Revenio Group Corporation: Revenio’s CEO has taken out a loan granted by the company to buy company shares
Revenio Group Corporation, Stock Exchange Release, June 11, 2020 at 10.15
Revenio’s CEO has taken out a loan granted by the company to buy company shares
Revenio Group Corporation's CEO Jouni Toijala has taken out a loan of EUR 50 000 granted by the company on market terms for the acquisition of Revenio’s shares. The shares acquired using the loan will act as security for the loan. The Board of Directors of the company finds it important for the commitment and motivation of the CEO that the CEO owns shares in the company. The CEO, then again, has undertaken to hold the company shares he has acquired using the loan financing granted by the company for five (5) years.
It has also been jointly agreed that the CEO’s obligation to hold the acquired shares ends if the CEO’s employment relationship ends before the end of such five-year period.
Revenio Group Corporation
Board of Directors
For further information, please contact:
Chairman of the Board Pekka Rönkä, tel. +358 40 826 4356
pekka.ronka@revenio.fi
www.revenio.fi
DISTRIBUTION:
Nasdaq Helsinki Ltd
Financial Supervisory Authority
Main media
www.revenio.fi
Revenio Group in brief
Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances.
The Revenio Group consists of Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.
The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group’s focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.
In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5 %. Revenio Group Corporation is listed on Nasdaq Helsinki.